Jake Xia

Hangzhou Qihan Biotech Co., Ltd. is a biotech company that applies genome-editing technology to develop novel cell therapies and organs for transplantation. The company is based in Hangzhou, China. The Chinese company's mission is to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other complex medical conditions. Qihan Biotech has raised two rounds of financing and is advancing its cell therapy programs into IND enabling investigations. It was founded in 2017 by Luhan Yang and George McDonald Church, with Luhan Yang serving as the CEO since then.

Hangzhou Qihan Biotech Co., Ltd. is a biotech company that applies genome-editing technology to develop novel cell therapies and organs for transplantation. The company is based in Hangzhou, China. The Chinese company's mission is to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other complex medical conditions. Qihan Biotech has raised two rounds of financing and is advancing its cell therapy programs into IND enabling investigations. It was founded in 2017 by Luhan Yang and George McDonald Church, with Luhan Yang serving as the CEO since then.

Hangzhou Qihan Biotech Co., Ltd. is a biotech company that applies genome-editing technology to develop novel cell therapies and organs for transplantation. The company is based in Hangzhou, China. The Chinese company's mission is to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other complex medical conditions. Qihan Biotech has raised two rounds of financing and is advancing its cell therapy programs into IND enabling investigations. It was founded in 2017 by Luhan Yang and George McDonald Church, with Luhan Yang serving as the CEO since then.

Hangzhou Qihan Biotech Co., Ltd. is a biotech company that applies genome-editing technology to develop novel cell therapies and organs for transplantation. The company is based in Hangzhou, China. The Chinese company's mission is to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other complex medical conditions. Qihan Biotech has raised two rounds of financing and is advancing its cell therapy programs into IND enabling investigations. It was founded in 2017 by Luhan Yang and George McDonald Church, with Luhan Yang serving as the CEO since then.

Hangzhou Qihan Biotech Co., Ltd. is a biotech company that applies genome-editing technology to develop novel cell therapies and organs for transplantation. The company is based in Hangzhou, China. The Chinese company's mission is to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other complex medical conditions. Qihan Biotech has raised two rounds of financing and is advancing its cell therapy programs into IND enabling investigations. It was founded in 2017 by Luhan Yang and George McDonald Church, with Luhan Yang serving as the CEO since then.